80 related articles for article (PubMed ID: 25560279)
1. Malignancies in pemphigus and pemphigoid diseases.
Schulze F; Neumann K; Recke A; Zillikens D; Linder R; Schmidt E
J Invest Dermatol; 2015 May; 135(5):1445-1447. PubMed ID: 25560279
[No Abstract] [Full Text] [Related]
2. Large-Scale Electron Microscopy Maps of Patient Skin and Mucosa Provide Insight into Pathogenesis of Blistering Diseases.
Sokol E; Kramer D; Diercks GFH; Kuipers J; Jonkman MF; Pas HH; Giepmans BNG
J Invest Dermatol; 2015 Jul; 135(7):1763-1770. PubMed ID: 25789704
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of antioxidant enzyme activity and antioxidant capacity in patients with newly diagnosed pemphigus vulgaris.
Javanbakht MH; Djalali M; Daneshpazhooh M; Zarei M; Eshraghian MR; Derakhshanian H; Chams-Davatchi C
Clin Exp Dermatol; 2015 Apr; 40(3):313-7. PubMed ID: 25683954
[TBL] [Abstract][Full Text] [Related]
4. The incidence of internal malignancies in pemphigus and bullous pemphigoid in Japan.
Ogawa H; Sakuma M; Morioka S; Kitamura K; Sasai Y; Imamura S; Inaba Y
J Dermatol Sci; 1995 Mar; 9(2):136-41. PubMed ID: 7772576
[TBL] [Abstract][Full Text] [Related]
5. Acute myeloid leukemia with paraneoplastic pemphigus successfully treated with a personalized antileukemic and immunosuppressive strategy.
Iovene FR; Santinelli E; Armiento D; Sarlo C; Bancone C; Silvestri L; Erculei S; Sanhust MG; Cristiano A; Fabiani E; Divona M; Page C; Di Zenzo G; Cantonetti M; Rigacci L
Ann Hematol; 2024 May; ():. PubMed ID: 38780802
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology of malignant tumors in patients with pemphigus: an analysis of trends from 1955 to 2021.
Luo Y; Fei X; Wang M; Yang H; Zhang Y; Chen Y; Luo Y; Ding X; Gao C; Shen F; Wang R; Li B; Kuai L; Zheng Q; Li M; Song J
Clin Exp Med; 2024 May; 24(1):100. PubMed ID: 38758217
[TBL] [Abstract][Full Text] [Related]
7. Pemphigus: trigger and predisposing factors.
Moro F; Sinagra JLM; Salemme A; Fania L; Mariotti F; Pira A; Didona B; Di Zenzo G
Front Med (Lausanne); 2023; 10():1326359. PubMed ID: 38213911
[TBL] [Abstract][Full Text] [Related]
8. Interventions for bullous pemphigoid.
Singh S; Kirtschig G; Anchan VN; Chi CC; Taghipour K; Boyle RJ; Murrell DF
Cochrane Database Syst Rev; 2023 Aug; 8(8):CD002292. PubMed ID: 37572360
[TBL] [Abstract][Full Text] [Related]
9. Comorbidity in bullous pemphigoid: up-date and clinical implications.
Huttelmaier J; Benoit S; Goebeler M
Front Immunol; 2023; 14():1196999. PubMed ID: 37457698
[TBL] [Abstract][Full Text] [Related]
10. Coexistence of malignancies in pemphigus vulgaris.
Warshavsky K; Zeeli T; Mekiten O; Sprecher E; Silverman BG; Barzilai A; Baum S
Immunol Res; 2023 Oct; 71(5):743-748. PubMed ID: 37142890
[TBL] [Abstract][Full Text] [Related]
11. Associations between bullous pemphigoid and hematological diseases: Literature review on mechanistic connections and possible treatments.
Yang Y; Zhao W; Yang N; Cui S; Jin H; Li L
Front Immunol; 2023; 14():1155181. PubMed ID: 36969223
[TBL] [Abstract][Full Text] [Related]
12. Prevalence, Spectrum and Clinical Implications of Malignancies in Patients with Bullous Pemphigoid.
Baum S; Steinberg S; Tzanani I; Barzilai A; Lyakhovitsky A
Acta Derm Venereol; 2023 Mar; 103():adv00888. PubMed ID: 36916952
[TBL] [Abstract][Full Text] [Related]
13. Epidermolysis Bullosa Acquisita-Current and Emerging Treatments.
Tešanović Perković D; Bukvić Mokos Z; Marinović B
J Clin Med; 2023 Feb; 12(3):. PubMed ID: 36769788
[TBL] [Abstract][Full Text] [Related]
14. What's new in the pathogeneses and triggering factors of bullous pemphigoid.
Ujiie H
J Dermatol; 2023 Feb; 50(2):140-149. PubMed ID: 36412277
[TBL] [Abstract][Full Text] [Related]
15. Hemidesmosomal Reactivity and Treatment Recommendations in Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid-A Retrospective, Monocentric Study.
Schauer F; Rafei-Shamsabadi D; Mai S; Mai Y; Izumi K; Meiss F; Kiritsi D
Front Immunol; 2022; 13():953546. PubMed ID: 35936009
[TBL] [Abstract][Full Text] [Related]
16. Clinical Patterns, Survival, Comorbidities, and Treatment Regimens in 149 Patients With Pemphigus in Tuscany (Italy): A 12-Year Hospital-Based Study.
Quintarelli L; Coi A; Maglie R; Corrà A; Mariotti EB; Aimo C; Ruffo di Calabria V; Verdelli A; Bianchi B; Del Bianco E; Antiga E; Caproni M
Front Immunol; 2022; 13():895490. PubMed ID: 35880183
[TBL] [Abstract][Full Text] [Related]
17. Comorbidities in Patients with Autoimmune Bullous Disorders: Hospital-Based Registry Study.
Sánchez-García V; Pérez-Alcaraz L; Belinchón-Romero I; Ramos-Rincón JM
Life (Basel); 2022 Apr; 12(4):. PubMed ID: 35455086
[TBL] [Abstract][Full Text] [Related]
18. Coincidence of Bullous Pemphigoid and Pityriasis Rubra Pilaris.
Gasslitter I; Löffler-Ragg J; Schmidt E; Schmuth M; Gruber R
Acta Derm Venereol; 2022 Mar; 102():adv00674. PubMed ID: 35170740
[No Abstract] [Full Text] [Related]
19. Bullous pemphigoid: An immune disorder related to aging (Review).
Deotto ML; Spiller A; Sernicola A; Alaibac M
Exp Ther Med; 2022 Jan; 23(1):50. PubMed ID: 34934428
[TBL] [Abstract][Full Text] [Related]
20. Bullous pemphigoid in diabetic patients treated by gliptins: the other side of the coin.
Chouchane K; Di Zenzo G; Pitocco D; Calabrese L; De Simone C
J Transl Med; 2021 Dec; 19(1):520. PubMed ID: 34930319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
